Does Bronchial Hyperresponsiveness in Asthma Matter?

References

• Pauwels R A, Lofdahl C G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–1411, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Barnes P J, Rodriguez‐Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392–1397, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Nelson H S, Busse W W, Kerwin E, Church N, Emmett A, Rickard K, Knobil K. Fluticasone propionate/salmeterol combination provides more effective asthma control than low‐dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 2000; 106: 1088–1095, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Calhoun W J, Nelson H S, Nathan R A, Pepsin P J, Kalberg C, Emmett A, Rickard K A, Dorinsky P. Comparison of fluticasone propionate‐salmeterol combination therapy and montelukast in patients who are symptomatic on short‐acting beta2‐agonists alone. Am J Respir Crit Care Med 2001; 164: 759–763, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta‐analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000; 320: 1368–1373, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ducharme F M. Anti‐leukotrienes as add‐on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ 2002; 324: 1545, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• The British Thoracic Society guidelines on asthma management: 1995 review and position statement. Thorax 1997; 52(suppl. 1)S1–S21
   PubMed Web of Science ®Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Publication No. 97‐4051. National Institutes of Health: Bethesda, MD, 1997
   Google Scholar
• Lipworth B J, Wilson A M. Dose–response to inhaled corticosteroids: benefits and risks. Semin Respir Crit Care Med 1998; 19: 625–646
   Web of Science ®Google Scholar
• Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose–response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta‐analysis. BMJ 2001; 323: 253–256, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Robinson D S, Bentley A M, Hartnell A, Kay A B, Durham S R. Activated memory T helper cells in bronchoalveolar lavage fluid from patients with atopic asthma: relation to asthma symptoms, lung function, and bronchial responsiveness. Thorax 1993; 48: 26–32, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wardlaw A J, Dunnette S, Gleich G J, Collins J V, Kay A B. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 62–69, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sont J K, Han J, van Krieken J M, Evertse C E, Hooijer R, Willems L N, Sterk P J. Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids. Thorax 1996; 51: 496–502, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gibson P G, Saltos N, Borgas T. Airway mast cells and eosinophils correlate with clinical severity and airway hyperresponsiveness in corticosteroid‐treated asthma. J Allergy Clin Immunol 2000; 105: 752–759, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Xu X, Niu T, Chen C, Wang B, Jin Y, Yang J, Weiss S T. Association of airway responsiveness with asthma and persistent wheeze in a Chinese population. Chest 2001; 119: 691–700, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Pattemore P K, Asher M I, Harrison A C, Mitchell E A, Rea H H, Stewart A W. The interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma, and asthma symptoms. Am Rev Respir Dis 1990; 142: 549–554, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Woolcock A J, Peat J K, Salome C M, Yan K, Anderson S D, Schoeffel R E, McCowage G, Killalea T. Prevalence of bronchial hyperresponsiveness and asthma in a rural adult population. Thorax 1987; 42: 361–368, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Weiss S T, Van Natta M L, Zeiger R S. Relationship between increased airway responsiveness and asthma severity in the childhood asthma management program. Am J Respir Crit Care Med 2000; 162: 50–56, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hunter C J, Brightling C E, Woltmann G, Wardlaw A J, Pavord I D. A comparison of the validity of different diagnostic tests in adults with asthma. Chest 2002; 121: 1051–1057, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goldstein M F, Veza B A, Dunsky E H, Dvorin D J, Belecanech G A, Haralabatos I C. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest 2001; 119: 1001–1010, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cockcroft D W, Marciniuk D D, Hurst T S, Cotton D J, Laframboise K F, McNab B D, Skomro R P. Methacholine challenge: test‐shortening procedures. Chest 2001; 120: 1857–1860, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Currie G P, Jackson C M, Lee D K, Lipworth B J. Determinants of airway hyperresponsiveness in mild asthma. Ann Allergy, Asthma, & Immun 2003; 90: 560–563, [CSA]
   PubMed Web of Science ®Google Scholar
• Currie G P, Jackson C M, Lee D K, Lipworth B J. Allergen sensitization and bronchial hyperresponsiveness to adenosine monophosphate in asthmatic patients. Clin Exp Allergy 2003; 33: 1405–1408, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Custovic A, Simpson A, Chapman M D, Woodcock A. Allergen avoidance in the treatment of asthma and atopic disorders. Thorax 1998; 53: 63–72, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Cockcroft D W. How best to measure airway responsiveness. Am J Respir Crit Care Med 2001; 163: 1514–1515, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Currie G P, Haggart K, Lee D K, Fowler S J, Wilson A M, Brannan J D, Anderson S D, Lipworth B J. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy 2003; 33: 783–788, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Brannan J D, Anderson S D, Gomes K, King G G, Chan H K, Seale J P. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med 2001; 163: 1420–1425, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Leuppi J D, Salome C M, Jenkins C R, Anderson S D, Xuan W, Marks G B, Koskela H, Brannan J D, Freed R, Andersson M, Chan H K, Woolcock A J. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 2001; 163: 406–412, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lotvall J, Inman M, O'Byrne P. Measurement of airway hyperresponsiveness: new considerations. Thorax 1998; 53: 419–424, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Wong A G, O'Shaughnessy A D, Walker C M, Sears M R. Effects of long‐acting and short‐acting beta‐agonists on methacholine dose–response curves in asthmatics. Eur Respir J 1997; 10: 330–336, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Godfrey S, Springer C, Noviski N, Maayan C, Avital A. Exercise but not methacholine differentiates asthma from chronic lung disease in children. Thorax 1991; 46: 488–492, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lim T K, Taylor R G, Watson A, Joyce H, Pride N B. Changes in bronchial responsiveness to inhaled histamine over four years in middle aged male smokers and ex‐smokers. Thorax 1988; 43: 599–604, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• De Meer G, Heederik D, Postma D S. Bronchial responsiveness to adenosine 5′‐monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV(1). Am J Respir Crit Care Med 2002; 165: 327–331, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Holgate S T. Adenosine provocation: a new test for allergic type airway inflammation. Am J Respir Crit Care Med 2002; 165: 317–318, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Van Den Berge M, Meijer R J, Kerstjens H A, de Reus D M, Koeter G H, Kauffman H F, Postma D S. PC(20) adenosine 5′‐monophosphate is more closely associated with airway inflammation in asthma than PC(20) methacholine. Am J Respir Crit Care Med 2001; 163: 1546–1550, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• van Den Toorn L M, Prins J B, Overbeek S E, Hoogsteden H C, de Jongste J C. Adolescents in clinical remission of atopic asthma have elevated exhaled nitric oxide levels and bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000; 162: 953–957, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wilson A M, Lipworth B J. Dose–response evaluation of the therapeutic index for inhaled budesonide in patients with mild‐to‐moderate asthma. Am J Med 2000; 108: 269–275, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• O'Connor B J, Ridge S M, Barnes P J, Fuller R W. Greater effect of inhaled budesonide on adenosine 5′‐monophosphate‐induced than on sodium‐metabisulfite‐induced bronchoconstriction in asthma. Am Rev Respir Dis 1992; 146: 560–564, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Fowler S J, Dempsey O J, Sims E J, Lipworth B J. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta2‐receptor genotype. Am J Respir Crit Care Med 2000; 162: 1318–1322, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lee D K, Bates C E, Currie G P, Lipworth B J. Comparative in vivo bioactivity of modern H1‐antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol 2003; 111: 337–341, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Anderson S D, Brannan J, Spring J, Spalding N, Rodwell L T, Chan K, Gonda I, Walsh A, Clark A R. A new method for bronchial‐provocation testing in asthmatic subjects using a dry powder of mannitol. Am J Respir Crit Care Med 1997; 156: 758–765, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Brannan J D, Koskela H, Anderson S D, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise‐ and hyperventilation‐induced asthma. Am J Respir Crit Care Med 1998; 158: 1120–1126, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Leuppi J D, Brannan J D, Anderson S D. Bronchial provocation tests: the rationale for using inhaled mannitol as a test for airway hyperresponsiveness. Swiss Med Wkly 2002; 132: 151–158, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Currie G P, Haggart K, Brannan J D, Lee D K, Anderson S D, Lipworth B J. Relationship between airway hyperresponsiveness to mannitol and adenosine monophosphate. Allergy 2003; 58: 762–766, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Holzer K, Anderson S D, Chan H K, Douglass J. Mannitol as a challenge test to identify exercise‐induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med 2003; 167: 534–537, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Vignola A M, Chanez P, Campbell A M, Souques F, Lebel B, Enander I, Bousquet J. Airway inflammation in mild intermittent and in persistent asthma. Am J Respir Crit Care Med 1998; 157: 403–409, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boulet L P, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest 1994; 105: 1024–1031, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Currie G P, Bates C E, Lee D K, Jackson C M, Lipworth B J. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. Eur J Clin Pharmacol 2003; 59: 11–15, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Currie G P, Jackson C M, Ogston S A, Lipworth B J. Airway‐stabilizing effect of long‐acting β2‐agonists as add on therapy to inhaled corticosteroids. QJM 2003; 96: 435–440, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Calhoun W J, Hinton K L, Kratzenberg J J. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. Am J Respir Crit Care Med 2001; 163: 881–886, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Gardiner P V, Ward C, Booth H, Allison A, Hendrick D J, Walters E H. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006–1011, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Roberts J A, Bradding P, Britten K M, Walls A F, Wilson S, Gratziou C, Holgate S T, Howarth P H. The long‐acting beta2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J 1999; 14: 275–282, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Lemanske R F, Jr., Sorkness C A, Mauger E A, Lazarus S C, Boushey H A, Fahy J V, Drazen J M, Chinchilli V M, Craig T, Fish J E, Ford J G, Israel E, Kraft M, Martin R J, Nachman S A, Peters S P, Spahn J D, Szefler S J. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285: 2594–2603, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Currie G P, Stenback S, Lipworth B J. Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003; 56: 11–17, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Currie G P, Fowler S J, Lipworth B J. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta‐analysis. Ann Allergy, Asthma, & Immun 2003; 90: 194–198
   PubMed Web of Science ®Google Scholar
• Hofstra W B, Neijens H J, Duiverman E J, Kouwenberg J M, Mulder P G, Kuethe M C, Sterk P J. Dose–responses over time to inhaled fluticasone propionate treatment of exercise‐ and methacholine‐induced bronchoconstriction in children with asthma. Pediatr Pulmonol 2000; 29: 415–423, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Currie G P, Lee D K, Haggart K, Bates C E, Lipworth B J. Effects of montelukast on surrogate inflammatory markers in corticosteroid‐treated patients with asthma. Am J Respir Crit Care Med 2003; 167: 1232–1238, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Currie G P, Lipworth B J. Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta‐analysis. Chest 2002; 122: 146–150, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dempsey O J, Kennedy G, Lipworth B J. Comparative efficacy and anti‐inflammatory profile of once‐daily therapy with leukotriene antagonist or low‐dose inhaled corticosteroid in patients with mild persistent asthma. J Allergy Clin Immunol 2002; 109: 68–74, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Dempsey O J, Fowler S J, Wilson A, Kennedy G, Lipworth B J. Effects of adding either a leukotriene receptor antagonist or low dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma. Chest 2002; 122: 151–159, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Polos P G. Montelukast or salmeterol added to fluticasone in uncontrolled asthma: a subgroup analysis of the IMPACT study. J Allergy Clin Immunol 2003; 111, abstract 227
   Google Scholar
• Vaquerizo M J, Casan P, Castillo J, Perpina M, Sanchis J, Sobradillo V, Valencia A, Verea H, Viejo J L, Villasante C, Gonzalez‐Esteban J, Picado C. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204–210, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lipworth B J, Jackson C M. Second‐line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids: the step 3 dilemma. Drugs 2002; 62: 2315–2332, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Sont J K, Willems L N, Bel E H, van Krieken J H, Vandenbroucke J P, Sterk P J. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long‐term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999; 159: 1043–1051, [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Green R H, Brightling C E, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw A J, Pavord I D. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715–1721, [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar